


**AMENDMENTS TO THE CLAIMS****IN THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application. Please amend the claims as follows.

1. (Currently Amended) A compound of Formula (I):



(I)

wherein

a and b are, independently, equal to 0 wherein the value of 0 represents a direct bond;

W is -N(R<sub>2</sub>)-,

wherein

R<sub>2</sub> is

- a) -alkyl;
- b) -L<sub>3</sub>-D-G;
- c) -L<sub>3</sub>-D-alkyl;
- d) -L<sub>3</sub>-D-aryl;
- e) -L<sub>3</sub>-D-heteroaryl;
- f) -L<sub>3</sub>-D-cycloalkyl;
- g) -L<sub>3</sub>-D-heterocyclyl;
- h) -L<sub>3</sub>-D-arylene-alkyl;
- i) -L<sub>3</sub>-D-alkylene-arylene-alkyl;
- j) -L<sub>3</sub>-D-alkylene-aryl;
- k) -L<sub>3</sub>-D-alkyl-G;
- l) -L<sub>3</sub>-D-aryl-G;

- m) – L<sub>3</sub>-D-heteroaryl-G;
- n) – L<sub>3</sub>-D-cycloalkyl-G;
- o) – L<sub>3</sub>-D-heterocyclyl-G;
- p) – L<sub>3</sub>-D-arylene-alkyl-G;
- q) – L<sub>3</sub>-D-alkylene-arylene-alkyl-G; or
- r) – L<sub>3</sub>-D-alkylene-aryl-G;

wherein

L<sub>3</sub> is an an –alkylene, –alkenylene, or alkynylene;


D is a direct bond, –CH<sub>2</sub>–, –O–, –N(R<sub>5</sub>)–, –C(O)–, –CON(R<sub>5</sub>)–, –N(R<sub>6</sub>)C(O)–, –N(R<sub>6</sub>)CON(R<sub>5</sub>)–, –N(R<sub>5</sub>)C(O)O–, –OC(O)N(R<sub>5</sub>)–, –N(R<sub>5</sub>)SO<sub>2</sub>–, –SO<sub>2</sub>N(R<sub>5</sub>)–, –C(O)O–, –O–C(O)–, –S–, –S(O)–, –S(O<sub>2</sub>)–, or –N(R<sub>5</sub>)SO<sub>2</sub>N(R<sub>6</sub>)–, –N=N–, or –N(R<sub>5</sub>)N(R<sub>6</sub>)–;

wherein

R<sub>5</sub> and R<sub>6</sub> are independently selected from the group consisting of:

–hydrogen, –alkyl, –aryl, –arylene-alkyl, –alkylene-aryl, and –alkylene-arylene-alkyl; and


G is hydrogen, –CN, –SO<sub>3</sub>H, –P(O)(OH)<sub>2</sub>, –P(O)(O-alkyl)(OH), –CO<sub>2</sub>H,



–CO<sub>2</sub>-alkyl, an acid isostere, –NR<sub>7</sub>R<sub>8</sub>, or ;

wherein

R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of:  
hydrogen, –alkyl, –L<sub>4</sub>-E-alkyl, –L<sub>4</sub>-E-aryl, –C(O)-alkyl, –C(O)-aryl, –SO<sub>2</sub>-alkyl, –SO<sub>2</sub>-aryl, and



wherein

$R_9$ ,  $R_{10}$ , and  $R_{11}$  are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

$L_4$  is a direct bond, -alkylene, -alkenylene, or -alkynylene;

$E$  is a direct bond,  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{N}(\text{R}_{12})-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{CON}(\text{R}_{12})-$ ,  $-\text{N}(\text{R}_{12})\text{C}(\text{O})-$ ,  $-\text{N}(\text{R}_{12})\text{CON}(\text{R}_{13})-$ ,  $-\text{N}(\text{R}_{12})\text{C}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}_{12})-$ ,  $-\text{N}(\text{R}_{12})\text{SO}_2-$ ,  $-\text{SO}_2\text{N}(\text{R}_{12})-$ ,  $-\text{C}(\text{O})-\text{O}-$ ,  $-\text{O}-\text{C}(\text{O})-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O}_2)-$ ,  $-\text{N}(\text{R}_{12})\text{SO}_2\text{N}(\text{R}_{13})-$ ,  $-\text{N}=\text{N}-$ , or  $-\text{N}(\text{R}_{12})-\text{N}(\text{R}_{13})-$

wherein


$R_{12}$  and  $R_{13}$  are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

$R_1$  is

- a) -hydrogen;
- b) -fluoro;
- c) -chloro;
- d) -bromo;
- e) -iodo;
- f) -cyano;
- g) -alkyl;
- h) -aryl;
- i) -alkylene-aryl;

- j) -heteroaryl;
- k) -alkylene-heteroaryl;
- l) -cycloalkyl;
- m) -alkylene-cycloalkyl
- n) - heterocyclyl; or
- o) - alkylene-heterocyclyl;

L<sub>1</sub> is selected from the group consisting of:



wherein R<sub>3</sub> and R<sub>4</sub> are independently selected from the group consisting of: hydrogen, chloro, fluoro, bromo, alkyl, aryl, -alkylene-aryl, cycloalkyl, -alkylene-cycloalkyl, -heterocyclyl, -alkylene-heterocyclyl, and -alkynylene;

Ar<sub>1</sub> is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -J-R<sub>14</sub>;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;

- m) -cycloalkyl;
- n) -L<sub>5</sub>-aryl;
- o) - L<sub>5</sub>-arylene-aryl;
- p) - L<sub>5</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -J-alkyl;
- t) -J-aryl;
- u) -J-alkylene-aryl;
- v) -J-arylene-alkyl;
- w) -J-alkylene-arylene-aryl;
- x) -J-arylene-arylene-aryl;
- y) -J-alkylene-arylene-alkyl;
- z) - L<sub>5</sub>-J-alkylene-aryl;
- aa) -arylene-J-alkyl;
- bb) - L<sub>5</sub>-J-aryl;
- cc) - L<sub>5</sub>-J-heteroaryl;
- dd) - L<sub>5</sub>-J-cycloalkyl;
- ee) - L<sub>5</sub>-J-heterocyclyl;
- ff) - L<sub>5</sub>-J-arylene-alkyl;
- gg) - L<sub>5</sub>-J-alkylene-arylene-alkyl;
- hh) - L<sub>5</sub>-J-alkyl;
- ii) - L<sub>5</sub>-J-R<sub>14</sub>; and
- jj) -arylene-J-R<sub>14</sub>;

wherein

L<sub>5</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

J is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>15</sub>)-, -C(O)-, -CON(R<sub>15</sub>)-, -N(R<sub>15</sub>)C(O)-, -N(R<sub>15</sub>)CON(R<sub>16</sub>)-, -N(R<sub>15</sub>)C(O)O-, -OC(O)N(R<sub>15</sub>)-, -N(R<sub>15</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>15</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>15</sub>)SO<sub>2</sub>N(R<sub>16</sub>)-, -N=N-, or -N(R<sub>15</sub>)N(R<sub>16</sub>)-,



wherein

R<sub>14</sub>, R<sub>15</sub>, and R<sub>16</sub> are independently selected from a group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl

Ar<sub>2</sub> is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -Q-R<sub>17</sub>;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L<sub>6</sub>-aryl;
- o) -L<sub>6</sub>-arylene-aryl;
- p) -L<sub>6</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -Q-alkyl;
- t) -Q-aryl;
- u) -Q-alkylene-aryl;
- v) -Q-arylene-alkyl;
- w) -Q-alkylene-arylene-aryl;
- x) -Q-arylene-arylene-aryl;
- y) -Q-alkylene-arylene-alkyl;
- z) -L<sub>6</sub>-Q-alkylene-aryl;
- aa) -arylene-Q-alkyl;
- bb) -L<sub>6</sub>-Q-aryl;
- cc) -L<sub>6</sub>-Q-heteroaryl;
- dd) -L<sub>6</sub>-Q-cycloalkyl;
- ee) -L<sub>6</sub>-Q-heterocyclyl;
- ff) -L<sub>6</sub>-Q-arylene-alkyl;

gg) -L<sub>6</sub>-Q-alkylene-arylene-alkyl;  
 hh) -L<sub>6</sub>-Q-alkyl;  
 ii) -L<sub>6</sub>-Q-alkylene-aryl-R<sub>17</sub>;  
 jj) -L<sub>6</sub>-Q-alkylene-heteroaryl-R<sub>17</sub>;  
 kk) -arylene-Q-alkylene-R<sub>17</sub>;  
 ll) -heteroarylene-Q-alkylene-R<sub>17</sub>;  
 mm) -L<sub>6</sub>-Q-aryl-R<sub>17</sub>;  
 nn) -L<sub>6</sub>-Q-heteroarylene-R<sub>17</sub>;  
 oo) -L<sub>6</sub>-Q-heteroaryl-R<sub>17</sub>;  
 pp) -L<sub>6</sub>-Q-cycloalkyl-R<sub>17</sub>;  
 qq) -L<sub>6</sub>-Q-heterocyclyl-R<sub>17</sub>;  
 rr) -L<sub>6</sub>-Q-arylene-alkyl-R<sub>17</sub>;  
 ss) -L<sub>6</sub>-Q-heteroarylene-alkyl-R<sub>17</sub>;  
 tt) -L<sub>6</sub>-Q-alkylene-arylene-alkyl-R<sub>17</sub>;  
 uu) -L<sub>6</sub>-Q-alkylene-heteroarylene-alkyl-R<sub>17</sub>;  
 vv) -L<sub>6</sub>-Q-alkylene-cycloalkylene-alkyl-R<sub>17</sub>;  
 ww) -L<sub>6</sub>-Q-alkylene-heterocyclylene-alkyl-R<sub>17</sub>;  
 xx) -L<sub>6</sub>-Q-alkyl-R<sub>17</sub>;  
 yy) -L<sub>6</sub>-Q-R<sub>17</sub>;  
 zz) -arylene-Q-R<sub>17</sub>;  
 aaa) -heteroarylene-Q-R<sub>17</sub>;  
 bbb) -heterocyclylene-Q-R<sub>17</sub>;  
 ccc) -Q-alkylene-R<sub>17</sub>;  
 ddd) -Q-arylene-R<sub>17</sub>;  
 eee) -Q-heteroarylene-R<sub>17</sub>;  
 fff) -Q-alkylene-arylene-R<sub>17</sub>;  
 ggg) -Q-alkylene-heteroarylene-R<sub>17</sub>;  
 hhh) -Q-heteroarylene-alkylene- R<sub>17</sub>;  
 iii) -Q-arylene-alkylene- R<sub>17</sub>;  
 jjj) -Q-cycloalkylene-alkylene- R<sub>17</sub>;  
 kkk) -Q-heterocyclylene-alkylene- R<sub>17</sub>;  
 III) -Q-alkylene-arylene-alkyl- R<sub>17</sub>;  
 mmm) -Q-alkylene-heteroarylene-alkyl- R<sub>17</sub>;



wherein


$L_8$  is a direct bond, -alkylene, -alkenylene, or -alkynylene;

$Q$  is a direct bond,  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{N}(\text{R}_{18})-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{CON}(\text{R}_{18})-$ ,  $-\text{N}(\text{R}_{18})\text{C}(\text{O})-$ ,  $-\text{N}(\text{R}_{18})\text{CON}(\text{R}_{19})-$ ,  $-\text{N}(\text{R}_{18})\text{C}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}_{18})-$ ,  $-\text{N}(\text{R}_{18})\text{SO}_2-$ ,  $-\text{SO}_2\text{N}(\text{R}_{18})-$ ,  $-\text{C}(\text{O})\text{O}-$ ,  $-\text{O}-\text{C}(\text{O})-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O}_2)-$ ,  $-\text{N}(\text{R}_{18})\text{SO}_2\text{N}(\text{R}_{19})-$ ,  $-\text{N}=\text{N}-$ , or  $-\text{N}(\text{R}_{18})-\text{N}(\text{R}_{19})-$ ;

wherein

$\text{R}_{18}$  and  $\text{R}_{19}$  are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

$V$  is



$Z$  is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

$\text{R}_{17}$  is  $-\text{SO}_3\text{H}$ ,  $-\text{P}(\text{O})(\text{OH})_2$ ,  $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{-alkyl}$ , an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl

$L_2$  is a direct bond,


$T$  is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of


- a) -fluoro;
- b) -chloro;



- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -U-R<sub>22</sub>;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L<sub>7</sub>-aryl;
- o) -L<sub>7</sub>-arylene-aryl;
- p) -L<sub>7</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -U-alkyl;
- t) -U-aryl;
- u) -U-alkylene-aryl;
- v) -U-arylene-alkyl;
- w) -U-alkylene-arylene-aryl;
- x) -U-arylene-arylene-aryl;
- y) -U-alkylene-arylene-alkyl;
- z) -L<sub>7</sub>-U-alkylene-aryl;
- aa) -arylene-U-alkyl;
- bb) -L<sub>7</sub>-U-aryl;
- cc) -L<sub>7</sub>-U-heteroaryl;
- dd) -L<sub>7</sub>-U-cycloalkyl;
- ee) -L<sub>7</sub>-U-heterocyclyl;
- ff) -L<sub>7</sub>-U-arylene-alkyl;
- gg) -L<sub>7</sub>-U-alkylene-arylene-alkyl;
- hh) -L<sub>7</sub>-U-alkyl;
- ii) -L<sub>7</sub>-U-alkylene-aryl- R<sub>22</sub>;
- jj) -L<sub>7</sub>-U-alkylene-heteroaryl- R<sub>22</sub>;

kk) -arylene-U-alkylene-  $R_{22}$ ;  
 ll) -heteroarylene-U-alkylene-  $R_{22}$ ;  
 mm) - $L_7$ -U-aryl-  $R_{22}$ ;  
 nn) - $L_7$ -U-heteroarylene-  $R_{22}$ ;  
 oo) - $L_7$ -U-heteroaryl-  $R_{22}$ ;  
 pp) - $L_7$ -U-cycloalkyl-  $R_{22}$ ;  
 qq) - $L_7$ -U-heterocyclyl-  $R_{22}$ ;  
 rr) - $L_7$ -U-arylene-alkyl-  $R_{22}$ ;  
 ss) - $L_7$ -U-heteroarylene-alkyl-  $R_{22}$ ;  
 tt) - $L_7$ -U-alkylene-arylene-alkyl-  $R_{22}$ ;  
 uu) - $L_7$ -U-alkylene-heteroarylene-alkyl-  $R_{22}$ ;  
 vv) - $L_7$ -Q-alkylene-cycloalkylene-alkyl- $R_{22}$ ;  
 ww) - $L_7$ -Q-alkylene-heterocyclylene-alkyl- $R_{22}$ ;  
 xx) - $L_7$ -U-alkyl-  $R_{22}$ ;  
 yy) - $L_7$ -U-  $R_{22}$ ;  
 zz) -arylene-U-  $R_{22}$ ;  
 aaa) -heteroarylene-U-  $R_{22}$ ;  
 bbb) -heterocyclylene-U-  $R_{22}$ ;  
 ccc) -U-alkylene-  $R_{22}$ ;  
 ddd) -U-arylene-  $R_{22}$ ;  
 eee) -U-heteroarylene-  $R_{22}$ ;  
 fff) -U-alkylene-arylene-  $R_{22}$ ;  
 ggg) -U-alkylene-heteroarylene-  $R_{22}$ ;  
 hhh) -U-heteroarylene-alkylene-  $R_{22}$ ;  
 iii) -U-arylene-alkylene-  $R_{22}$ ;  
 jjj) -U-cycloalkylene-alkylene-  $R_{22}$ ;  
 kkk) -U-heterocyclylene-alkylene-  $R_{22}$ ;  
 ll) -U-alkylene-arylene-alkyl-  $R_{22}$ ;  
 mmm) -U-alkylene-heteroarylene-alkyl-  $R_{22}$ ;





wherein


$L_7$  is a direct bond, -alkylene, -alkenylene, or -alkynylene;

$U$  is a direct bond,  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{N}(\text{R}_{23})-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{CON}(\text{R}_{23})-$ ,  $-\text{N}(\text{R}_{23})\text{C}(\text{O})-$ ,  $-\text{N}(\text{R}_{23})\text{CON}(\text{R}_{24})-$ ,  $-\text{N}(\text{R}_{23})\text{C}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}_{23})-$ ,  $-\text{N}(\text{R}_{23})\text{SO}_2-$ ,  $-\text{SO}_2\text{N}(\text{R}_{23})-$ ,  $-\text{C}(\text{O})\text{O}-$ ,  $-\text{O}-\text{C}(\text{O})-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O}_2)-$ ,  $-\text{N}(\text{R}_{23})\text{SO}_2\text{N}(\text{R}_{24})-$ ,  $-\text{N}=\text{N}-$ , or  $-\text{N}(\text{R}_{23})-\text{N}(\text{R}_{24})-$ ;

wherein

$\text{R}_{23}$  and  $\text{R}_{24}$  are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

$X$  is



$Y$  is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocycl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

$\text{R}_{22}$  is  $-\text{SO}_3\text{H}$ ,  $-\text{P}(\text{O})(\text{OH})_2$ ,  $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{-alkyl}$ , an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

2. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $W$  is  $-\text{N}(\text{R}_2)-$ , wherein  $\text{R}_2$  is alkyl, or  $-\text{L}_3\text{-D-alkylene-aryl}$ , wherein  $\text{L}_3$  is alkylene, and  $\text{D}$  is  $-\text{CO}(\text{NR}_5)-$ , wherein  $\text{R}_5$  is hydrogen.

3. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $\text{R}_1$  is hydrogen or aryl.

4. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $R_1$  is hydrogen.

5-6. (Canceled)

7. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $Ar_1$  is a phenyl group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) - $J-R_{14}$ ;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) - $L_5$ -aryl;
- o) -  $L_5$ -arylene-aryl;
- p) -  $L_5$ -arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -J-alkyl;
- t) -J-aryl;
- u) -J-alkylene-aryl;
- v) -J-arylene-alkyl;
- w) -J-alkylene-arylene-aryl;
- x) -J-arylene-arylene-aryl;
- y) -J-alkylene-arylene-alkyl;

- z) - L<sub>5</sub>-J-alkylene-aryl;
- aa) -arylene-J-alkyl;
- bb) - L<sub>5</sub>-J-aryl;
- cc) - L<sub>5</sub>-J-heteroaryl;
- dd) - L<sub>5</sub>-J-cycloalkyl;
- ee) - L<sub>5</sub>-J-heterocyclyl;
- ff) - L<sub>5</sub>-J-arylene-alkyl;
- gg) - L<sub>5</sub>-J-alkylene-arylene-alkyl;
- hh) - L<sub>5</sub>-J-alkyl;
- ii) - L<sub>5</sub>-J-R<sub>14</sub>; and
- jj) -arylene-J-R<sub>14</sub>;

wherein

L<sub>5</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

J is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>15</sub>)-, -C(O)-, -CON(R<sub>15</sub>)-, -N(R<sub>15</sub>)C(O)-, -N(R<sub>15</sub>)CON(R<sub>16</sub>)-, -N(R<sub>15</sub>)C(O)O-, -OC(O)N(R<sub>15</sub>)-, -N(R<sub>15</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>15</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>15</sub>)SO<sub>2</sub>N(R<sub>16</sub>)-, -N=N-, or -N(R<sub>15</sub>)-N(R<sub>16</sub>)-,

wherein

R<sub>14</sub>, R<sub>15</sub>, and R<sub>16</sub> are independently selected from a group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl.

8. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar<sub>1</sub> is a phenyl group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:



- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro; and
- g) -aryl.

9. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $Ar_1$  is a phenyl group substituted 1 to 5 times, wherein the substituents are selected from the group consisting of: -chloro and -fluoro.

10. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $Ar_2$  is a phenylene group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -Q- $R_{17}$ ;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) - $L_6$ -aryl;
- o) - $L_6$ -arylene-aryl;
- p) - $L_6$ -arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -Q-alkyl;
- t) -Q-aryl;
- u) -Q-alkylene-aryl;
- v) -Q-arylene-alkyl;
- w) -Q-alkylene-arylene-aryl;
- x) -Q-arylene-arylene-aryl;

- y) -Q-alkylene-arylene-alkyl;
- z) -L<sub>6</sub>-Q-alkylene-aryl;
- aa) -arylene-Q-alkyl;
- bb) -L<sub>6</sub>-Q-aryl;
- cc) -L<sub>6</sub>-Q-heteroaryl;
- dd) -L<sub>6</sub>-Q-cycloalkyl;
- ee) -L<sub>6</sub>-Q-heterocyclyl;
- ff) -L<sub>6</sub>-Q-arylene-alkyl;
- gg) -L<sub>6</sub>-Q-alkylene-arylene-alkyl;
- hh) -L<sub>6</sub>-Q-alkyl;
- ii) -L<sub>6</sub>-Q-alkylene-aryl-R<sub>17</sub>;
- jj) -L<sub>6</sub>-Q-alkylene-heteroaryl-R<sub>17</sub>;
- kk) -arylene-Q-alkylene-R<sub>17</sub>;
- ll) -heteroarylene-Q-alkylene-R<sub>17</sub>;
- mm) -L<sub>6</sub>-Q-aryl-R<sub>17</sub>;
- nn) -L<sub>6</sub>-Q-heteroarylene-R<sub>17</sub>;
- oo) -L<sub>6</sub>-Q-heteroaryl-R<sub>17</sub>;
- pp) -L<sub>6</sub>-Q-cycloalkyl-R<sub>17</sub>;
- qq) -L<sub>6</sub>-Q-heterocyclyl-R<sub>17</sub>;
- rr) -L<sub>6</sub>-Q-arylene-alkyl-R<sub>17</sub>;
- ss) -L<sub>6</sub>-Q-heteroarylene-alkyl-R<sub>17</sub>;
- tt) -L<sub>6</sub>-Q-alkylene-arylene-alkyl-R<sub>17</sub>;
- uu) -L<sub>6</sub>-Q-alkylene-heteroarylene-alkyl-R<sub>17</sub>;
- vv) -L<sub>6</sub>-Q-alkylene-cycloalkylene-alkyl-R<sub>17</sub>;
- ww) -L<sub>6</sub>-Q-alkylene-heterocyclylene-alkyl-R<sub>17</sub>;
- xx) -L<sub>6</sub>-Q-alkyl-R<sub>17</sub>;
- yy) -L<sub>6</sub>-Q-R<sub>17</sub>;
- zz) -arylene-Q-R<sub>17</sub>;
- aaa) -heteroarylene-Q-R<sub>17</sub>;
- bbb) -heterocyclylene-Q-R<sub>17</sub>;
- ccc) -Q-alkylene-R<sub>17</sub>;
- ddd) -Q-arylene-R<sub>17</sub>;
- eee) -Q-heteroarylene-R<sub>17</sub>;
- fff) -Q-alkylene-arylene-R<sub>17</sub>;

ggg) -Q-alkylene-heteroarylene- $R_{17}$ ;hhh) -Q-heteroarylene-alkylene-  $R_{17}$ ;iii) -Q-arylene-alkylene-  $R_{17}$ ;jjj) -Q-cycloalkylene-alkylene-  $R_{17}$ ;kkk) -Q-heterocyclylene-alkylene-  $R_{17}$ lll) -Q-alkylene-arylene-alkyl-  $R_{17}$ ;mmm) -Q-alkylene-heteroarylene-alkyl-  $R_{17}$ ;

wherein


 $L_6$  is a direct bond, -alkylene, -alkenylene, or -alkynylene;

Q is a direct bond,  $-CH_2-$ ,  $-O-$ ,  $-N(R_{18})-$ ,  $-C(O)-$ ,  $-CON(R_{18})-$ ,  $-N(R_{18})C(O)-$ ,  $-N(R_{18})CON(R_{19})-$ ,  $-N(R_{18})C(O)O-$ ,  $-OC(O)N(R_{18})-$ ,  $-N(R_{18})SO_2-$ ,  $-SO_2N(R_{18})-$ ,  $-C(O)O-$ ,  $-O-C(O)-$ ,  $-S-$ ,  $-S(O)-$ ,  $-S(O_2)-$ ,  $-N(R_{18})SO_2N(R_{19})-$ ,  $-N=N-$ , or  $-N(R_{18})-N(R_{19})-$ ;

wherein

$R_{18}$  and  $R_{19}$  are independently selected from the group consisting of: -  
hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and  
-alkylene-arylene-alkyl;

V is



Z is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;



$R_{17}$  is  $-\text{SO}_3\text{H}$ ,  $-\text{P}(\text{O})(\text{OH})_2$ ,  $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{-alkyl}$ , an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

11. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $\text{Ar}_2$  is a phenyl group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q- $R_{17}$ ;
- f) -alkyl;
- g) -aryl;
- h) -arylene-alkyl;
- i) -Q-alkyl; and
- j) -arylene-Q-alkyl;

wherein

Q is  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{C}(\text{O})-$ , or  $-\text{C}(\text{O})-\text{O}-$ , and

$R_{17}$  is: -hydrogen, -alkyl, -aryl,  $-\text{CO}_2\text{H}$ , or an acid isostere.

12. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $\text{Ar}_2$  is a phenyl group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q- $R_{17}$ ;
- f) -alkyl;

- g) -phenyl;
- h) -phenylene-alkyl;
- i) -Q-alkyl; and
- j) -phenylene-Q-alkyl;

wherein

Q is:  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{C}(\text{O})-$ , or  $-\text{C}(\text{O})-\text{O}-$ , and

$\text{R}_{17}$  is: -hydrogen, -alkyl, -phenyl, or  $-\text{CO}_2\text{H}$ .



13-15. (Canceled)

16. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein T is an aryl group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h)  $-\text{U}-\text{R}_{22}$ ;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n)  $-\text{L}_7\text{-aryl}$ ;
- o)  $-\text{L}_7\text{-arylene-aryl}$ ;
- p)  $-\text{L}_7\text{-arylene-alkyl}$ ;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -U-alkyl;

- t) -U-aryl;
- u) -U-alkylene-aryl;
- v) -U-arylene-alkyl;
- w) -U-alkylene-arylene-aryl;
- x) -U-arylene-arylene-aryl;
- y) -U-alkylene-arylene-alkyl;
- z) -L<sub>7</sub>-U-alkylene-aryl;
- aa) -arylene-U-alkyl;
- bb) -L<sub>7</sub>-U-aryl;
- cc) -L<sub>7</sub>-U-heteroaryl;
- dd) -L<sub>7</sub>-U-cycloalkyl;
- ee) -L<sub>7</sub>-U-heterocyclyl;
- ff) -L<sub>7</sub>-U-arylene-alkyl;
- gg) -L<sub>7</sub>-U-alkylene-arylene-alkyl;
- hh) -L<sub>7</sub>-U-alkyl;
- ii) -L<sub>7</sub>-U-alkylene-aryl- R<sub>22</sub>;
- jj) -L<sub>7</sub>-U-alkylene-heteroaryl- R<sub>22</sub>;
- kk) -arylene-U-alkylene- R<sub>22</sub>;
- ll) -heteroarylene-U-alkylene- R<sub>22</sub>;
- mm) -L<sub>7</sub>-U-aryl- R<sub>22</sub>;
- nn) -L<sub>7</sub>-U-heteroarylene- R<sub>22</sub>;
- oo) -L<sub>7</sub>-U-heteroaryl- R<sub>22</sub>;
- pp) -L<sub>7</sub>-U-cycloalkyl- R<sub>22</sub>;
- qq) -L<sub>7</sub>-U-heterocyclyl- R<sub>22</sub>;
- rr) -L<sub>7</sub>-U-arylene-alkyl- R<sub>22</sub>;
- ss) -L<sub>7</sub>-U-heteroarylene-alkyl- R<sub>22</sub>;
- tt) -L<sub>7</sub>-U-alkylene-arylene-alkyl- R<sub>22</sub>;
- uu) -L<sub>7</sub>-U-alkylene-heteroarylene-alkyl- R<sub>22</sub>;
- vv) -L<sub>7</sub>-Q-alkylene-cycloalkylene-alkyl-R<sub>22</sub>;
- ww) -L<sub>7</sub>-Q-alkylene-heterocyclylene-alkyl-R<sub>22</sub>;
- xx) -L<sub>7</sub>-U-alkyl- R<sub>22</sub>;
- yy) -L<sub>7</sub>-U- R<sub>22</sub>;
- zz) -arylene-U- R<sub>22</sub>;
- aaa) -heteroarylene-U- R<sub>22</sub>;

- bbb) -heterocyclylene-U-  $R_{22}$ ;  
 ccc) -U-alkylene-  $R_{22}$ ;  
 ddd) -U-arylene-  $R_{22}$ ;  
 eee) -U-heteroarylene-  $R_{22}$ ;  
 fff) -U-alkylene-arylene-  $R_{22}$ ;  
 ggg) -U-alkylene-heteroarylene-  $R_{22}$ ;  
 hhh) -U-heteroarylene-alkylene-  $R_{22}$ ;  
 iii) -U-arylene-alkylene-  $R_{22}$ ;  
 jjj) -U-cycloalkylene-alkylene-  $R_{22}$ ;  
 kkk) -U-heterocyclylene-alkylene-  $R_{22}$ ;  
 III) -U-alkylene-arylene-alkyl-  $R_{22}$ ;  
 mmm) -U-alkylene-heteroarylene-alkyl-  $R_{22}$ ;



wherein


$L_7$  is a direct bond, -alkylene, -alkenylene, or -alkynylene;

U is a direct bond,  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{N}(\text{R}_{23})-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{CON}(\text{R}_{23})-$ ,  $-\text{N}(\text{R}_{23})\text{C}(\text{O})-$ ,  $-\text{N}(\text{R}_{23})\text{CON}(\text{R}_{24})-$ ,  $-\text{N}(\text{R}_{23})\text{C}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}_{23})-$ ,  $-\text{N}(\text{R}_{23})\text{SO}_2-$ ,  $-\text{SO}_2\text{N}(\text{R}_{23})-$ ,  $-\text{C}(\text{O})\text{O}-$ ,  $-\text{O}-\text{C}(\text{O})-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O}_2)-$ ,  $-\text{N}(\text{R}_{23})\text{SO}_2\text{N}(\text{R}_{24})-$ ,  $-\text{N}=\text{N}-$ , or  $-\text{N}(\text{R}_{23})-\text{N}(\text{R}_{24})-$ ;

wherein

$\text{R}_{23}$  and  $\text{R}_{24}$  are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

X is




Y is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R<sub>22</sub> is -SO<sub>3</sub>H, -P(O)(OH)<sub>2</sub>, -P(O)(O-alkyl)(OH), -CO<sub>2</sub>H, -CO<sub>2</sub>-alkyl, an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

17. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein T is an aryl group substituted by -U-alkylene-R<sub>22</sub>, wherein U is -O- or a direct bond, and R<sub>22</sub> is -CO<sub>2</sub>H or an acid isostere.

18. (Currently Amended) The compound of Formula (I) according to claim 16 or a pharmaceutically acceptable salt or solvate thereof, wherein

a and b are equal to zero;



Ar<sub>2</sub> is a phenylene group optionally substituted 1 time with a group consisting of:  
-Q-alkyl, wherein Q is -O-;

L<sub>2</sub> is a direct bond; and

T is an aryl group substituted with at least one substituent selected from the group consisting of:

- a) -U-R<sub>22</sub>;
- b) -U-alkylene-arylene-R<sub>22</sub>;
- c) -U-alkylene-R<sub>22</sub>;
- d) -U-arylene-R<sub>22</sub>;
- e) -U-arylene-R<sub>22</sub> wherein the arylene is substituted with at least one of a halogen, methanesulfonylamino, or trifluoromethanesulfonylamino group;
- f) -U-arylene wherein the arylene is substituted with at least one trifluoromethanesulfonylamino group;
- g) -R<sub>22</sub>; and

h) -halogen;  
wherein  $R_{22}$  is  $-CO_2H$  or an acid isostere.

19. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein

a and b are equal to zero;

$R_1$  is hydrogen;

W is  $-N(R_2)-$ , wherein  $R_2$  is alkyl; and

$Ar_1$  is phenyl substituted 2 times wherein the substituent groups are -chloro.

20. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein W is  $-N(R_2)-$ , wherein

$R_2$  is -alkylene-arylene-G,

wherein

G is  $-CN$ ,  $-SO_3H$ ,  $-P(O)(OH)_2$ ,  $-P(O)(O-alkyl)(OH)$ ,  $-CO_2H$ ,  $-CO_2-$  alkyl, or an acid isostere.

21. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein a and b are equal to 0, and T,  $L_2$ ,  $Ar_2$ , and  $L_1$  together form a group selected from a group consisting of:

(E)-2-(1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-methoxy-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(3'-methoxy-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-carboxymethoxy-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-(3-methoxycarbonyl-1-propyloxy)-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-(3-carboxy-1-propyloxy)-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-phenoxy-1,1'-biphenyl-4-yl)vinyl, and

(E)-2-(4'-benzyloxy-1,1'-biphenyl-4-yl)vinyl.

22. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein  $Ar_1$  is: 2,4-dichlorophenyl.

23. (Currently Amended) The compound of Formula (I) according to claim 1, where the compound of Formula (I) is:

4-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-3-fluoro-biphenyl-4-yloxy-methyl)-benzoic acid;

4-[4'-[2-[4-(2,4-dichloro-phenyl)-1-[(1-naphthalen-1-yl-ethylcarbamoyl)-methyl] 1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy]-butyric acid;

4-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-butyric acid;

5-(4'-[2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-pentanoic acid

2-bromo-4-(4'-[2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-benzoic acid;

4-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy-methyl)-benzoic acid;

4-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-benzoic acid;

2-bromo-4-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-benzoic acid;

4-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-3-methanesulfonylamino-benzoic acid;

4-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-3-trifluoromethanesulfonyl-amino-benzoic acid;

5-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-2-methanesulfonylamino-benzoic acid;

5-(4'-[2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-2-trifluoromethane-sulfonylamino-benzoic acid; or

4-(4'-[2-[4-(2,4-Dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl]-biphenyl-4-yloxy)-butyric acid 2,2-dimethyl-propionyloxymethyl ester,

or a pharmaceutically acceptable salt or solvate thereof.

24. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1.

25. (Previously Presented) The pharmaceutical composition of claim 24, wherein said pharmaceutical composition is a topical formulation.

26-63. (Canceled).